: Tooth whitening is a relatively conservative and effective option to treat discolored teeth. However, questions remain whether in-office or at-home tooth whitening products with short treatment durations are as effective and stable as products with longer treatment durations. : Forty human third molars with intact enamel surfaces were divided into four groups of ten each, subjected to discoloration challenges with coffee for 60 h, and they were treated with four professional tooth whitening systems: two for take-home use-6% hydrogen peroxide for 30 min/d for a total of 7 h in 14 days (HP6), 10% carbamide peroxide for 10 h/d for 140 h in 14 days (CP10), as well as two for in-office use-35% HP for 10 min × 3 (HP35) for a total of 30 min and 40% HP for 20 min × 3 (HP40) for a total of 60 min. Teeth colors were assessed in the CIE L*a*b* color space with a spectrophotometer immediately and six months after whitening treatments. Surface roughness (Sa) for the treated and untreated enamel surfaces of the teeth in all groups were evaluated with a three-dimensional laser scanning microscope after six months. : No significant differences were found between HP6 and CP10 groups immediately after whitening (∆ 10.6 ± 1.6 vs. 11.4 ± 1.7, > 0.05) and at six months after treatments (∆ 9.0 ± 1.9 vs. 9.2 ± 2.5, > 0.05), or between HP35 and HP40 groups immediately after whitening (∆ 5.9 ± 1.2 vs. 5.3 ± 1.7, > 0.05) and at six months after treatments (∆ 7.2 ± 1.6 vs. 7.7 ± 1.3, > 0.05). The two at-home whitening systems achieved significantly better whitening outcomes than the two in-office products immediately after whitening ( < 0.05). However, at six months after treatments, the differences between at-home and in-office treatments had narrowed significantly ( > 0.05). There were no statistically significant differences with respect to the Sa values between the treated and untreated surfaces ( > 0.05). : Tooth whitening products in the same product category have similar whitening efficacies, despite significant differences in treatment durations (7 vs. 140 h, and 30 min vs. 60 min, respectively). Take-home products achieved better whitening outcomes than in-office products, but they needed 14 to 280 times longer treatment durations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302806 | PMC |
http://dx.doi.org/10.3390/medicina59061130 | DOI Listing |
J Med Econ
January 2025
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
AimsThe cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D).
View Article and Find Full Text PDFHematology
December 2025
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.
Objective: To evaluate the short-term efficacy and safety of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China.
Method: Data were retrospectively collected from patients with PNH who received at least 3 months of full-dose eculizumab. Changes in clinical and laboratory indicators after 1, 3, and 6 months of eculizumab therapy and at the end of follow-up were documented.
Front Med (Lausanne)
January 2025
Department of Respiratory Medicine, Faculty of Medicine, Kyorin University, Tokyo, Japan.
Background: There is a paucity of real-world data on patients with interstitial lung diseases (ILDs) that are progressive, other than idiopathic pulmonary fibrosis (IPF), including treatment patterns and attitudes toward treatment. This study aimed to investigate the diagnosis, clinical characteristics, treatment paradigm and current decision-making practices of IPF and progressive pulmonary fibrosis (PPF) in a Japanese real-world setting.
Methods: Data were drawn from the Adelphi Real World PPF-ILD Disease Specific Programme™, a cross-sectional survey with retrospective data collection of pulmonologists and rheumatologists in Japan from April to October 2022.
Bull World Health Organ
February 2025
Dean's Office, Medical College, Aga Khan University, Karachi, Pakistan.
Objective: To develop a tele-intensive care service providing peer-to-peer teleconsultation for physicians in remote and resource-constrained health-care settings for treatment of critically ill patients, and to evaluate the outcomes of the service.
Methods: The Aga Khan University started the coronavirus disease 2019 (COVID-19) tele-intensive care unit in 2020. A central command centre used two-way audiovisual technology to connect experienced intensive care specialists to clinical teams in remote hospital settings.
Heliyon
January 2025
Department of Emergency, Dali Bai Autonomous Prefecture People's Hospital, Dali, Yunnan, 671000, China.
Background: Approximately 20%-50 % of individuals with autoimmune encephalitis (AE) demonstrate suboptimal responses to first-line therapies, leading to persistent neurological deficits and the need for second-line interventions. Although rituximab has shown potential as an alternative treatment in AE, the existing evidence remains insufficient. This study systematically evaluated and meta-analyzed the efficacy of rituximab in AE patients who either failed or exhibited inadequate responses to first-line treatments, aiming to refine and optimize therapeutic strategies for AE.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!